用于重组药物蛋白生产的人源化细胞系研究进展  

Research progress of human cell lines for recombinant pharmaceutical protein production

作　　者：李琴[1] 王天云[2] 王小引[2] 郭潇 林艳 LI Qin;WANG Tian-Yun;WANG Xiao-Yin;GUO Xiao;LIN Yan(Analysis ＆ Test Laboratory,School of Basic MedicalSciences,Xinxiang Medical University,Xinxiang 453003,Chin)

机构地区：[1]新乡医学院基础医学院分析测试实验室,新乡453003 [2]新乡医学院生物化学与分子生物学教研室,新乡453003 [3]新乡医学院三全学院药学院,新乡453003 [4]新乡医学院护理学院,新乡453003

出　　处：《中国免疫学杂志》2018年第8期1274-1277,1281,共5页Chinese Journal of Immunology

基　　金：国家自然基金项目(No.81673337);河南省高校科技创新团队支持计划(No.18IRTSTHN027);新乡医学院新进博士科研启动资助项目(No.XYBSKYZZ201648)

摘　　要：哺乳动物细胞表达系统由于存在翻译后加工修饰(PTMs)机制,能够产生分子量大、结构复杂的蛋白,是重组药物蛋白生产的优选系统。虽然非人源化的哺乳动物细胞系的PTMs与人源化细胞类似,但仍能进行人源化细胞不存在的其他PTMs,表达药物蛋白存在免疫原性、改变药物代谢动力学等缺点。近年来,人源化的细胞系已经用于治疗重组药物蛋白的生产,此类细胞系的优点在于具备和人源细胞完全一致的PTMs,表达的蛋白活性高、疗效好。目前用于重组药物蛋白生产及临床前研究的人源细胞系主要有HEK293、HT-1080、PER.C6等。本文综述了人源化细胞用于重组药物蛋白的最新进展。Mammalian cell expression systems are the preferred systems for pharmaceutical protein production,as these cell lines are able to produce large,complex proteins with post-translational modifications（ PTMs） similar to those produced in human. However,these non-human cell lines also produce PTMs that are not expressed in humans,which may lead to increased immunogenicity and altered pharmacokinetics of these products when used in humans. In recent years,the human cell lines have been used in the recombinant pharmaceutical protein production,and the advantages of such cell lines have the same PTMs as human cells. Currently,the major human cell lines,such as HEK293,HT-1080,PER C6,etc have being used in production of recombinant pharmaceutical proteins and preclinical research. This paper reviews recent research progress of the human cells used in recombinant pharmaceutical protein.

关 键 词：表达系统 重组药物蛋白 人源化细胞 翻译后加工修饰 

分 类 号：R915[医药卫生—微生物与生化药学]